A Phase 1, Randomized, Double-Blind, Placebo- and Positive-Controlled, Thorough QT Study to Evaluate the Effect of Ampreloxetine on Cardiac Repolarization in Healthy Subjects
Latest Information Update: 22 Apr 2021
Price :
$35 *
At a glance
- Drugs Ampreloxetine (Primary) ; Moxifloxacin
- Indications Orthostatic hypotension
- Focus Adverse reactions
- Sponsors Theravance Biopharma
- 19 Apr 2021 Status changed from recruiting to completed.
- 25 Feb 2021 Planned End Date changed from 10 Mar 2021 to 1 Mar 2021.
- 25 Feb 2021 Planned primary completion date changed from 25 Feb 2021 to 1 Mar 2021.